» Articles » PMID: 3591659

Inhalation Toxicity Studies with 1,3-butadiene. 3. Two Year Toxicity/carcinogenicity Study in Rats

Overview
Date 1987 May 1
PMID 3591659
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

Groups of 110 male and 110 female CD (Sprague-Dawley) rats were exposed to atmospheres containing 0 (control), 1000 or 8000 ppm v/v butadiene for 6 hr/day and 5 days/week. Ten of each sex from each group were killed at 52 weeks. The study was terminated when it was predicted that survival would drop to 20% to 25% (105 weeks for females and 111 weeks for males). High dose rats had wet, ruffled fur and showed slight incoordination during the first exposure each week. During the second year, mortality in both treated female groups was increased because of humanitarian sacrifice of animals with large subcutaneous masses, while increased mortality in the high dose males was accompanied by an increase of the severity of nephropathy. Body weight was slightly lower than controls in both sexes at the high dose, but statistically significant only over the first 12 weeks. There were no effects in hematological analyses or tests of neuromuscular function that definitely could be associated with treatment. Liver weights at both doses were increased in both sexes with no associated pathological change. Kidney weight was increased in males at the high dose, together with an increase in the severity of nephrosis. There were increases in the incidences of pancreatic exocrine adenoma (high dose, male); uterine sarcoma (both doses, female); Zymbal gland carcinoma (high dose, female); mammary tumors (both doses, female); thyroid follicular cell tumors; and testis Leydig-cell tumors (high dose). These data suggest that butadiene is a weak oncogen to the rat under the conditions of exposure used in this study.

Citing Articles

Association of Urinary N7-(1-hydroxyl-3-buten-1-yl) Guanine (EB-GII) Adducts and Butadiene-Mercapturic Acids with Lung Cancer Development in Cigarette Smokers.

Jokipii Krueger C, Park S, Patel Y, Stram D, Aldrich M, Cai Q Chem Res Toxicol. 2024; 37(2):374-384.

PMID: 38315500 PMC: 11491053. DOI: 10.1021/acs.chemrestox.3c00336.


Isotope Labeling Mass Spectrometry to Quantify Endogenous and Exogenous DNA Adducts and Metabolites of 1,3-Butadiene In Vivo.

Jokipii Krueger C, Moran E, Tessier K, Tretyakova N Chem Res Toxicol. 2023; 36(8):1409-1418.

PMID: 37477250 PMC: 11009968. DOI: 10.1021/acs.chemrestox.3c00141.


Use of Biomarker Data and Relative Potencies of Mutagenic Metabolites to Support Derivation of Cancer Unit Risk Values for 1,3-Butadiene from Rodent Tumor Data.

Kirman C, Hays S Toxics. 2022; 10(7).

PMID: 35878299 PMC: 9316621. DOI: 10.3390/toxics10070394.


Occupational Safety Analysis for COVID-Instigated Repurposed Manufacturing Lines: Use of Nanomaterials in Injection Moulding.

Damilos S, Saliakas S, Kokkinopoulos I, Karayannis P, Karamitrou M, Trompeta A Polymers (Basel). 2022; 14(12).

PMID: 35745994 PMC: 9228191. DOI: 10.3390/polym14122418.


Benchmark Dose Modeling Approaches for Volatile Organic Chemicals Using a Novel Air-Liquid Interface In Vitro Exposure System.

Speen A, Murray J, Krantz Q, Davies D, Evansky P, Harrill J Toxicol Sci. 2022; 188(1):88-107.

PMID: 35426944 PMC: 9704371. DOI: 10.1093/toxsci/kfac040.